Beta Blockers for Peripheral Arterial Disease

Paravastu, Sharath; Mendonca, de; Silva, A. da

doi:10.1016/j.ejvs.2009.02.019

Cited by 52 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available evidence and extrapolation from the ALLHAT study suggests that major BP-lowering drug classes including diuretics, CCBs and RAS blockers prevent LEAD events with equal efficacy [1276,1277]. Therapeutic use also includes BBs (not primarily tested in ALLHAT) because these drugs have not been shown to worsen the symptoms of intermittent claudication in two metaanalyses [1278,1279]. In an RCT with the vasodilating beta-1 selective BB nebivolol and the nonvasodilating beta-1 selective BB metoprolol in patients with stable claudication [1280], both treatments were well tolerated, and there were no differences in quality of life, ABI and claudication distance.…”

Section: Management Of Patients With Cognitive Dysfunction and Dementiamentioning

confidence: 99%

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

744

280

View full text Add to dashboard Cite

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis (Greece), Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine (Turkey), Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering (Poland), Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos (Greece), Kazuomi Kario (Japan), Vasilios Kotsis (Greece), Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack (UK), Paolo Mulatero (Italy), Dike B. Ojji (Nigeria), Sungha Park (South Korea), Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz (Poland), Venkata Ram (India), Ramiro Sanchez (Argentina), Markus Schlaich (Australia), Alta Schutte (Australia), Cristina Sierra (Spain), Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios (Greece), Bruno Trimarco (Italy), Thomas Unger (The Netherlands), Bert-Jan van den Born (The Netherlands), Anna Vachulova (Slovak Republic), Agostino Virdis (Italy), Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton (USA), Jiri Widimsky (Czech Republic), Jacek Wolf (Poland), Grégoire Wuerzner (Switzerland), Eugene Yang (USA), Yuqing Zhang (China).

show abstract

Section: Management Of Patients With Cognitive Dysfunction and Dementiamentioning

confidence: 99%

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

744

280

View full text Add to dashboard Cite

show abstract

“…In the observational study, treatment of patients after myocardial infarction with beta-adrenolytics significantly reduced the risk of coronary events by 53% [62]. Using drugs from this class did not affect the claudication distance in patients with mild or moderate LEAD [63]. However, caution is recommended when using those drugs in patients with critical ischemia, despite the fact that in the observational studies, even in patients with CLTI the clinical outcomes of treatment were non-inferior among the patients treated with beta-adrenolytics to patients not receiving those drugs [64,65].…”

Section: Pharmacotherapy Of Arterial Hypertension In Patients With Lomentioning

confidence: 93%

The position of Polish experts on conservative management in patients with artery diseases of lower limbs

Krasiński¹,

Gaciong

Szymański

et al. 2019

Acta Angiologica

View full text Add to dashboard Cite

Peripheral artery disease (PAD) is a common disease, though not very well known and often diagnosed on a very late stage, causing not only typical complications such as intermittent claudication, critical limb ischemia or amputations, but also to cardiovascular mortality. The risk of cardiovascular death can be even 11 times higher in patients with symptomatic PAD than in healthy patients. The risk of heart attack, stroke or cardiovascular death is even higher, reaching almost 4% within one year, nearly equal to the risk for patients with coronary artery disease (CAD). In those patients, the 5-year mortality risk is estimated at 10-15%, with cardiovascular disorders being the most likely cause of death. In patients with critical limb ischemia, the risk of cardiovascular death within one year can be as high as 25% and the risk of amputation-30%. It is estimated that the global population of patients with PAD is over 120 million. The incidence of the diseases is 3-10%, but in patients aged 70 and more, the incidence increases to 14-29%. In Poland, around 4,000 people are hospitalized every year for PAD of lower limbs. The number of PAD-related amputations is over 9,000 per year. Although the methods of PAD diagnosis (e.g. ABI) are often easy and non-invasive, they are scarcely used in clinical practice. Also, optimal conservative management in the form of quitting smoking, modifying the cardiovascular risk factors and supervised exercise is often overlooked. PAD is a major issue not only for vascular surgery, but also for many other medical specializations, including angiology, general medicine, cardiology, or diabetology. As a result of long waiting times for the next visit and lack of access to patient programmes and reimbursed drugs, patients with PAD often report to the doctor when their condition is very serious. Despite the 2017 ESC guidelines on the diagnosis and treatment of peripheral artery disease, prepared together with ESVS, not all healthcare professionals have access to the latest knowledge on PAD diagnosis and treatment. Unfortunately, though published recently, the ESC's guidelines do not include some of the recent studies, among them the possibly breakthrough COMPASS trial which has the potential to change the paradigm of management of patients with PAD. We must bear in mind that the population with PAD is a difficult patient group who need new treatment methods and optimization of the existing ones in order to visibly improve diagnosis, treatment and prognosis.

show abstract

“…In general, beta-blockers are relatively contraindicated to avoid worsening of PAD symptoms. However, some reports have revealed that beta-blockers do not aggravate the symptoms in patients with mild to moderate PAD Therefore, beta-blockers are effective in PAD patients with co-existing ischemic heart disease or tachycardia [ 98 , 99 ]. Renal artery stenosis is frequently observed in patients with HTN and PAD.…”

Section: Hypertension In Special Situationsmentioning

confidence: 99%

2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations

et al. 2019

View full text Add to dashboard Cite

Treatment of hypertension improves cardiovascular, renal, and cerebrovascular outcomes. However, the benefit of treatment may be different according to the patients’ characteristics. Additionally, the target blood pressure or initial drug choice should be customized according to the special conditions of the hypertensive patients. In this part III, we reviewed previous data and presented recommendations for some special populations such as diabetes mellitus, chronic kidney disease, elderly people, and cardio-cerebrovascular disease.

show abstract

Beta Blockers for Peripheral Arterial Disease

Cited by 52 publications

References 13 publications

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

The position of Polish experts on conservative management in patients with artery diseases of lower limbs

2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations

Contact Info

Product

Resources

About